Dramatic response to catumaxomab treatment for malign ascites related to renal cell carcinoma with sarcomotoid differentiation.
![Thumbnail](/xmlui/bitstream/handle/11446/786/Dramatic%20response%20to%20catumaxomab%20treatment%20for%20malign.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/embargoedAccessDate
2014Author
Pilancı, Kezban NurOrdu, Çetin
Akpınar, Haluk
Balcı, Cem
Başsülü, Nuray
Köksal, Ülkühan İner
Demir, Osman Gökhan
Metadata
Show full item recordCitation
Pilanci KN, Ordu C, Akpinar H, Balci C, Başsülü N, Köksal UI, Elbüken F, Okutur K, Bülbül G, Sağlam S, Demir G. Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation. Am J Ther. 2014.Abstract
Refractory malignant ascites (MA) is a common complication in cancer patients. Renal cell carcinoma
(RCC) is rarely present with peritoneal ascites, which is commonly associated with carcinomas of the
gastrointestinal and female reproductive tracts; including especially ovarian high-grade serous carcinoma. Currently, chemotherapy and paracentesis represent the most widely used methods to
relieve the symptoms. Recently, intraperitoneal therapy with catumaxomab—a trifunctional hybrid
antibody—has been introduced for the treatment of MA. The benefit of this treatment has been
demonstrated in patients with distinct abdominal malignancies. In this case report, we present the
first case of successful catumaxomab treatment against MA in a patient with advanced RCC with
sarcomatoid differentiation. After the second administration of catumaxomab, paracentesis became
no longer necessary. Catumaxomab might represent a safe treatment option for MA in the course of
metastatic RCC with sarcomatoid differentiation.